A feasibility study of low-dose total body irradiation for relapsed canine lymphoma
A feasibility study of low-dose total body irradiation for relapsed canine lymphoma
复制标题
DOI：
10.1111/j.1476-5810.2006.00095.x
复制
发表时间：
2006-06-01
影响因子：
2.1
通讯作者：
Frimberger, A. E.
中科院分区：
文献类型：
--
作者：
Brown, E. M.;Ruslander, D. M.;Frimberger, A. E.
7只确诊为复发性淋巴瘤的客户拥有的犬入组了一项前瞻性可行性研究，研究了以1戈伊单次剂量进行低剂量全身照射（LDTBI）的效果。LDTBI治疗复发性淋巴瘤安全、耐受性好。LDTBI的唯一主要副作用是所有犬的无症状血小板减少症。中位血小板最低值为17 000/mu L（范围4000-89 000），发生在照射后中位10天（范围8-30）。3只犬有短期部分缓解，2只疾病稳定，2只疾病进展（PD）。6只犬因PD被人道处死，1只犬在部分缓解时死亡。无犬出现临床并发症。未进行生存分析，因为研究设计不允许评价生存时间。需要进行在治疗的诱导/巩固阶段纳入LDTBI的更大规模研究，以确定LDTBI的治疗效果。
Seven client owned dogs with confirmed relapsed lymphoma were enrolled in a prospective feasibility study investigating the effects of low-dose total body irradiation (LDTBI) delivered in a single 1 Gy fraction. LDTBI for relapsed lymphoma was safe and well tolerated. The only major side-effect of LDTBI was asymptomatic thrombocytopenia in all dogs. The median platelet nadir was 17 000/mu L (range 4000-89 000), which occurred a median of 10 days (range 8-30) post irradiation. Three dogs had short-term partial responses, two stable disease and two progressive disease (PD). Six dogs were euthanatized for PD, and one dog died while in partial remission. No dogs had clinical complications. Survival analysis was not performed, because the study design did not allow for evaluation of survival time. Larger studies incorporating LDTBI in the induction/consolidation phase of treatment need to be performed to determine the therapeutic efficacy of LDTBI.